Hilleman Laboratories is a global vaccine research & development organization focused on making affordable vaccines using innovation to address gaps that exist in low resource settings. Hilleman Labs acts as a catalyst in bridging the gap between academic research and product development by targeting novel vaccines and increasing the efficiency of existing vaccines.Know More
Developing vaccines for global health
Hilleman Laboratories is committed to developing high impact, affordable vaccines for people in developing countries in an innovative and sustainable manner.
Hilleman Labs successfully completes Phase I/II Clinical Trial of its Heat Stable Rotavirus Vaccine (HSRV)
October 12th, 2017
Making headway towards providing the developing nations an affordable and easy-to-use Heat Stable RoKnow More
Hilleman Labs achieves successful outcome of Phase I/II Clinical Trial of its Oral Cholera Vaccine Hillchol
October 12th, 2017
Delivering on its mission to develop affordable vaccines for global health, Hilleman Laboratories toKnow More
Hilleman Laboratories receives Indo-Swedish grant for developing - Oral Cholera Vaccine (OCV)
September 28th, 2017
28th September, 2017, New Delhi: Hilleman Laboratories, a joint-venture partnership between MSD andKnow More
Building Healthy Partnership
May 04th, 2017
Though India has scored several successes such as eradication of polio and reduction in the rates ofKnow More
Hilleman Laboratories signs MoU with NICED, ICMR to develop Shigella Vaccine
March 29th, 2017
March 29th, 2017, New Delhi: Hilleman Laboratories, a joint-venture partnership between MSD and WellKnow More
We have established modern research and development laboratories to play a crucial role in the process of health development in India and other under-developed countries.
We are collaborating with the global public health community on the development of optimized vaccines with target product profiles relevant to low income countries.
The World Health Organization estimates that 600,000 children under the age of 5 die annually due to rotavirus diarrhoea and another two million are hospitalized.